Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Finance

Dental implants maker Straumann's organic sales rises in third quarter

Published by Global Banking and Finance Review

Posted on October 29, 2025

Featured image for article about Finance

By Cian Muenster and Bartosz Dabrowski

(Reuters) -Swiss dental implant maker Straumann reported an 8.3% rise in third-quarter organic sales on Wednesday, slightly above market expectations, as growth in most Asia-Pacific markets and North America outweighed muted demand in China.

Revenue climbed to 602.2 million Swiss francs ($759.3 million) in the July-September period, compared with analysts' estimate of 600.6 million Francs in a Vara consensus.

Shares of the company rose 5.8% to 92.86 francs post results.

The company's Asia Pacific sales came in at 144.3 million francs, below consensus estimates of 151.5 million francs. The region accounts for about a quarter of Straumann's total sales.

The company said its revenue in China has begun to soften as patients delay treatment and distributors reduce inventories ahead of the next round of the country's volume-based procurement (VBP).

"We still have to see, and we will have more information by the end of the year when the Chinese authorities will publish how they would like to run this new VBP round for dental implants," CEO Guillaume Daniellot told Reuters in an interview.

Straumann said it is bracing for challenges in China over the next two quarters but remains optimistic about other regions.

"We believe that we can, of course, compensate for some of the shortfall that we would see in China based on really good results and growth in the rest of the geographies," Daniellot added.

Sales in North America stood at 161.6 million francs, nearly in line with estimates of 159.6 million, as premium and challenger brands gained traction, supported by commercial execution.

The company also announced new collaborations in its orthodontics business, transferring clear aligner manufacturing for EMEA and APAC to Smartee, its partner in China.

Straumann confirmed its full-year outlook and said it continues to expect high single-digit organic revenue growth in 2025.

($1 = 0.7931 Swiss francs)

(Reporting by Cian Muenster and Bartosz Dabrowski; Editing by Sumana Nandy)